BREAKWATER
BREAKWATER: Phase III Study of First-line Encorafenib + Cetuximab + Chemotherapy vs SoC for BRAF V600E–Mutant mCRC

Released: February 04, 2025

Expiration: August 03, 2025

Activity

Progress
1
Course Completed